CART-19 / Shanghai Unicar - LARVOL DELTA

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL (ASH 2023) - P1/2 | "In this phase 1/2 clinical trial conducted at two centers, we compared the efficacy and safety of ssCART-19 to classical CART-19 cells (cCART-19) in patients with r/r B-ALL (NCT03919240)...Lymphodepletion (fludarabine at 30 mg/m2/day and cyclophosphamide at 300 mg/m2/day) was conducted on days -5, -4, and -3 before infusion... Our clinical studies demonstrated the safety and high efficacy of ssCART-19 with IL-6 gene silencing in patients with relapsed/refractory B-ALL. These findings support the potential of ssCART-19 as a promising therapeutic approach for this challenging patient population."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia • IL2 • IL6 • TNFA

HIGH EFFICACY AND SAFETY OF INTERLEUKIN-6-KNOCKDOWN CD19-TARGETED CAR T CELLS IN RELAPSED/REFRACTORY B-ALL PATIENTS (EHA 2024) - P1/2 | "Aims: We compared the efficacy and safety of ssCART-19 to classical CART-19 cells (cCART-19) in patients with r/r B-ALL...All patients received lymphodepleting fludarabine and cyclophosphamideprior to CAR-T cells infusion... ssCART-19 is the first-in-world novel safe CAR-T product that firstly incorporates shRNA gene silencingtechnology to CAR-T technology. Notably, ssCART-19 shows good clinical efficacy and safety in B-ALL patientsincluding CNS-L patients. These clinical findings support the potential of ssCART-19 as a promising therapeuticapproach for r/r B-ALL patients."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia • IL6

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Trial completion date: Jan 2024 ➔ Dec 2025 | Trial primary completion date: Jan 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology